Triplet Therapeutics

Founded with the mission to develop transformational treatments for repeat expansion disorders (REDs), Triplet Therapeutics focuses on a group of over 50 genetic diseases, including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, and fragile X syndrome. The company leverages advanced biotechnology to address the underlying genetic causes of these conditions, aiming to provide innovative therapeutic solutions that significantly improve patient outcomes.

Triplet Therapeutics has garnered attention through its association with leading experts in genetics and biotechnology. Notable investors include prominent venture capital firms specializing in life sciences. The company has achieved significant milestones in preclinical research and has initiated clinical trials for its lead candidates. Triplet Therapeutics' pioneering approach has the potential to revolutionize treatment paradigms for genetic disorders, making a substantial impact on the lives of affected individuals and their families.